Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Clinical Trial

Sleep Disturbance, Irritability, and Response to Lurasidone Treatment in Children and Adolescents with Bipolar Depression

Author(s): Manpreet K. Singh*, Cynthia Siu, Michael Tocco, Andrei Pikalov and Antony Loebel

Volume 21, Issue 6, 2023

Published on: 14 November, 2022

Page: [1393 - 1404] Pages: 12

DOI: 10.2174/1570159X20666220927112625

Price: $65

Abstract

Background: The presence of mixed (subsyndromal hypomanic) symptoms may influence treatment outcomes in pediatric bipolar depression. This post-hoc analysis investigated “bridge” symptoms that have cross-sectional and predictive associations with depressive and manic symptom clusters in youth with bipolar depression.

Methods: The moderating effects of these bridge symptoms on the response to flexibly dosed lurasidone 20-80 mg/d compared to placebo treatment was analyzed in children and adolescents with bipolar I depression in a six-week, placebo-controlled, double-blind study followed by a 2-year, openlabel extension study of lurasidone.

Results: Sleep disturbances, assessed by “difficulty with sleep” (Children’s Depression Rating Scale, Revised [CDRS-R] item 4) and “decreased need for sleep” (Young Mania Rating Scale [YMRS] item 4), and “irritability” (CDRS-R item-8, YMRS item 5) were identified as “bridge” symptoms and found to have replicable causal associations with depressive (CDRS-R total) and manic symptom clusters (YMRS total) at baseline and week-6. A greater improvement in overall depression severity at week 6 with lurasidone (vs. placebo) treatment was observed in the presence (vs. absence) of decreased need for sleep at study baseline, mediated in part by significant reductions from study baseline in decreased need for sleep and manic symptom severity. The absence of sleep disturbance and irritability in patients at open-label extension study baseline was associated with higher rates of sustained recovery (symptomatic and functional remission) over 6 months compared to patients with those symptoms at baseline (68% vs. 50%, Number Needed to Treat=6).

Conclusion: Our findings suggest that sleep disturbance and irritability are cardinal symptoms that “bridge” between depressive and manic symptom clusters and influence treatment outcomes in youth with bipolar depression.

Keywords: mixed mood, hypomania, depression, lurasidone, bridge symptoms, network analysis

« Previous Next »
Graphical Abstract

[1]
Saxena, K.; Kurian, S.; Saxena, J.; Goldberg, A.; Chen, E.; Simonetti, A. Mixed states in early-onset bipolar disorder. Psychiatr. Clin. North Am., 2020, 43(1), 95-111.
[http://dx.doi.org/10.1016/j.psc.2019.10.009] [PMID: 32008691]
[2]
Janiri, D.; Conte, E.; De Luca, I.; Simone, M.V.; Moccia, L.; Simonetti, A.; Mazza, M.; Marconi, E.; Monti, L.; Chieffo, D.P.R.; Kotzalidis, G.; Janiri, L.; Sani, G. Not only mania or depression: Mixed states/mixed features in paediatric bipolar disorders. Brain Sci., 2021, 11(4), 434.
[http://dx.doi.org/10.3390/brainsci11040434] [PMID: 33805270]
[3]
Swann, A.C.; Bowden, C.L.; Morris, D.; Calabrese, J.R.; Petty, F.; Small, J.; Dilsaver, S.C.; Davis, J.M. Depression during mania. Treatment response to lithium or divalproex. Arch. Gen. Psychiatry, 1997, 54(1), 37-42.
[http://dx.doi.org/10.1001/archpsyc.1997.01830130041008] [PMID: 9006398]
[4]
Frye, M.A.; Helleman, G.; McElroy, S.L.; Altshuler, L.L.; Black, D.O.; Keck, P.E., Jr; Nolen, W.A.; Kupka, R.; Leverich, G.S.; Grunze, H.; Mintz, J.; Post, R.M.; Suppes, T. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am. J. Psychiatry, 2009, 166(2), 164-172.
[http://dx.doi.org/10.1176/appi.ajp.2008.08030322] [PMID: 19015231]
[5]
Goldberg, J.F.; Perlis, R.H.; Bowden, C.L.; Thase, M.E.; Miklowitz, D.J.; Marangell, L.B.; Calabrese, J.R.; Nierenberg, A.A.; Sachs, G.S. Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am. J. Psychiatry, 2009, 166(2), 173-181.
[http://dx.doi.org/10.1176/appi.ajp.2008.08050746] [PMID: 19122008]
[6]
Stahl, S.M.; Morrissette, D.A.; Faedda, G.; Fava, M.; Goldberg, J.F.; Keck, P.E.; Lee, Y.; Malhi, G.; Marangoni, C.; McElroy, S.L.; Ostacher, M.; Rosenblat, J.D.; Solé, E.; Suppes, T.; Takeshima, M.; Thase, M.E.; Vieta, E.; Young, A.; Zimmerman, M.; McIntyre, R.S. Guidelines for the recognition and management of mixed depression. CNS Spectr., 2017, 22(2), 203-219.
[http://dx.doi.org/10.1017/S1092852917000165] [PMID: 28421980]
[7]
Fried, E.I.; Nesse, R.M. Depression is not a consistent syndrome: An investigation of unique symptom patterns in the STAR*D study. J. Affect. Disord., 2015, 172, 96-102.
[http://dx.doi.org/10.1016/j.jad.2014.10.010] [PMID: 25451401]
[8]
Goldberg, J.F.; Siu, C.; Mao, Y.; Tsai, J.; Pikalov, A.; Calabrese, J.R.; Loebel, A. Major depressive disorder with mixed features and treatment response to lurasidone: A symptom network model. J. Affect. Disord., 2020, 277, 1045-1054.
[http://dx.doi.org/10.1016/j.jad.2020.08.048] [PMID: 33065813]
[9]
Young, R.C.; Biggs, J.T.; Ziegler, V.E.; Meyer, D.A. A rating scale for mania: Reliability, validity and sensitivity. Br. J. Psychiatry, 1978, 133(5), 429-435.
[http://dx.doi.org/10.1192/bjp.133.5.429] [PMID: 728692]
[10]
Cramer, A.O.J.; Waldorp, L.J.; van der Maas, H.L.J.; Borsboom, D. Comorbidity: A network perspective. Behav. Brain Sci., 2010, 33(2-3), 137-150.
[http://dx.doi.org/10.1017/S0140525X09991567] [PMID: 20584369]
[11]
Ishibashi, T.; Horisawa, T.; Tokuda, K.; Ishiyama, T.; Ogasa, M.; Tagashira, R.; Matsumoto, K.; Nishikawa, H.; Ueda, Y.; Toma, S.; Oki, H.; Tanno, N.; Saji, I.; Ito, A.; Ohno, Y.; Nakamura, M. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J. Pharmacol. Exp. Ther., 2010, 334(1), 171-181.
[http://dx.doi.org/10.1124/jpet.110.167346] [PMID: 20404009]
[12]
DelBello, M.P.; Goldman, R.; Phillips, D.; Deng, L.; Cucchiaro, J.; Loebel, A. Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: A double-blind, placebo-controlled study. J. Am. Acad. Child Adolesc. Psychiatry, 2017, 56(12), 1015-1025.
[http://dx.doi.org/10.1016/j.jaac.2017.10.006] [PMID: 29173735]
[13]
Singh, M.K.; Pikalov, A.; Siu, C.; Tocco, M.; Loebel, A. Lurasidone in children and adolescents with bipolar depression presenting with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J. Child Adolesc. Psychopharmacol., 2020, 30(10), 590-598.
[http://dx.doi.org/10.1089/cap.2020.0018] [PMID: 32392455]
[14]
Comsa, M.; Anderson, K.N.; Sharma, A.; Yadav, V.C.; Watson, S. The relationship between sleep and depression and bipolar disorder in children and young people. BJPsych Open, 2022, 8(1), e27.
[http://dx.doi.org/10.1192/bjo.2021.1076] [PMID: 35027099]
[15]
Montgomery, S.A.; Åsberg, M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry, 1979, 134(4), 382-389.
[http://dx.doi.org/10.1192/bjp.134.4.382] [PMID: 444788]
[16]
DelBello, M.P.; Tocco, M.; Pikalov, A.; Deng, L.; Goldman, R. Tolerability, safety, and effectiveness of two years of treatment with lurasidone in children and adolescents with bipolar depression. J. Child Adolesc. Psychopharmacol., 2021, 31(7), 494-503.
[http://dx.doi.org/10.1089/cap.2021.0040] [PMID: 34324397]
[17]
Kaufman, J.; Birmaher, B.; Brent, D.; Rao, U.; Flynn, C.; Moreci, P.; Williamson, D.; Ryan, N. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. J. Am. Acad. Child Adolesc. Psychiatry, 1997, 36(7), 980-988.
[http://dx.doi.org/10.1097/00004583-199707000-00021] [PMID: 9204677]
[18]
Poznanski, E.O.; Mokros, H.B. Children’s depression rating scale–revised: Manual; Western Psychological Services: Los Angeles, 1996.
[19]
Bird, H.R.; Canino, G.; Rubio-Stipec, M.; Ribera, J.C. Further measures of the psychometric properties of the Children’s Global Assessment Scale. Arch. Gen. Psychiatry, 1987, 44(9), 821-824.
[http://dx.doi.org/10.1001/archpsyc.1987.01800210069011] [PMID: 3632256]
[20]
Loebel, A.; Siu, C.; Rajagopalan, K.; Pikalov, A.; Cucchiaro, J.; Ketter, T.A. Recovery in bipolar depression: Post-hoc analysis of a placebo-controlled lurasidone trial followed by a long-term continuation study. J. Affect. Disord., 2015, 186, 376-382.
[http://dx.doi.org/10.1016/j.jad.2015.07.033] [PMID: 26363720]
[21]
Tibshirani, R. Regression shrinkage and selection via the lasso. J. R. Stat. Soc. B, 1996, 58(1), 267-288.
[http://dx.doi.org/10.1111/j.2517-6161.1996.tb02080.x]
[22]
Friedman, J.; Hastie, T.; Tibshirani, R. Sparse inverse covariance estimation with the graphical lasso. Biostatistics, 2008, 9(3), 432-441.
[http://dx.doi.org/10.1093/biostatistics/kxm045] [PMID: 18079126]
[23]
Epskamp, S.; Cramer, A.O.J.; Waldorp, L.J.; Schmittmann, V.D.; Borsboom, D. Network visualizations ofrelationships in psychometric data. J. Stat. Softw., 2012, 48(4), 1-18.
[http://dx.doi.org/10.18637/jss.v048.i04]
[24]
Foygel, R.; Drton, M. Extended bayesian information criteria for gaussian graphical models. Adv. Neural Inf. Process. Syst., 2010, 23, 2020-2028.
[25]
Patino, L.R.; DelBello, M.P. Irritability, anger, and aggression in the context of pediatric bipolar disorderChild Adolesc Psychiatr Clin N Am., 2021, 30(3), 561-571.
[http://dx.doi.org/10.1016/j.chc.2021.04.007] [PMID: 34053686]
[26]
Van Meter, A.; Correll, C.U.; Ahmad, W.; Dulin, M.; Saito, E. Symptoms and characteristics of youth hospitalized for depression: subthreshold manic symptoms can help differentiate bipolar from unipolar depression. J. Child Adolesc. Psychopharmacol., 2021, 31(8), 545-552.
[http://dx.doi.org/10.1089/cap.2021.0057] [PMID: 34637626]
[27]
Freeman, D.; Sheaves, B.; Waite, F.; Harvey, A.G.; Harrison, P.J. Sleep disturbance and psychiatric disorders. Lancet Psychiatry, 2020, 7(7), 628-637.
[http://dx.doi.org/10.1016/S2215-0366(20)30136-X] [PMID: 32563308]
[28]
Konac, D.; Young, K.S.; Lau, J.; Barker, E.D. Comorbidity between depression and anxiety in adolescents: Bridge symptoms and relevance of risk and protective factors. J. Psychopathol. Behav. Assess., 2021, 43(3), 583-596.
[http://dx.doi.org/10.1007/s10862-021-09880-5] [PMID: 34720388]
[29]
Forbes, M.K.; Wright, A.G.C.; Markon, K.E.; Krueger, R.F. The network approach to psychopathology: Promise versus reality. World Psychiatry, 2019, 18(3), 272-273.
[http://dx.doi.org/10.1002/wps.20659] [PMID: 31496101]
[30]
Harvey, A.G. Insomnia, psychiatric disorders, and the transdiagnostic perspective. Curr. Dir. Psychol. Sci., 2008, 17(5), 299-303.
[http://dx.doi.org/10.1111/j.1467-8721.2008.00594.x]
[31]
Gold, A.; Sylvia, L. The role of sleep in bipolar disorder. Nat. Sci. Sleep, 2016, 8, 207-214.
[http://dx.doi.org/10.2147/NSS.S85754] [PMID: 27418862]
[32]
Plante, D.T.; Winkelman, J.W. Sleep disturbance in bipolar disorder: Therapeutic implications. Am. J. Psychiatry, 2008, 165(7), 830-843.
[http://dx.doi.org/10.1176/appi.ajp.2008.08010077] [PMID: 18483132]
[33]
Raison, C.L.; Siu, C.; Pikalov, A.; Tocco, M.; Loebel, A. C-reactive protein and response to lurasidone treatment in children and adolescents with bipolar I depression: Results from a placebo-controlled trial. Brain Behav. Immun., 2020, 84, 269-274.
[http://dx.doi.org/10.1016/j.bbi.2019.12.010] [PMID: 31857217]
[34]
Raison, C.L.; Pikalov, A.; Siu, C.; Tsai, J.; Koblan, K.; Loebel, A. C-reactive protein and response to lurasidone in patients with bipolar depression. Brain Behav. Immun., 2018, 73, 717-724.
[http://dx.doi.org/10.1016/j.bbi.2018.08.009] [PMID: 30102967]
[35]
Rossetti, A.C.; Paladini, M.S.; Colombo, M.; Gruca, P.; Lason-Tyburkiewicz, M.; Tota-Glowczyk, K.; Papp, M.; Riva, M.A.; Molteni, R. Chronic stress exposure reduces parvalbumin expression in the rat hippocampus through an imbalance of redox mechanisms: Restorative effect of the antipsychotic lurasidone. Int. J. Neuropsychopharmacol., 2018, 21(9), 883-893.
[http://dx.doi.org/10.1093/ijnp/pyy046] [PMID: 29788232]
[36]
Luoni, A.; Macchi, F.; Papp, M.; Molteni, R.; Riva, M.A. Lurasidone exerts antidepressant properties in the chronic mild stress model through the regulation of synaptic and neuroplastic mechanisms in the rat prefrontal cortex. Int. J. Neuropsychopharmacol., 2015, 18(4), pyu061.
[http://dx.doi.org/10.1093/ijnp/pyu061] [PMID: 25522402]
[37]
Spero, V.; Paladini, M.S.; Brivio, P.; Riva, M.A.; Calabrese, F.; Molteni, R. Altered responsiveness of the antioxidant system in chronically stressed animals: Modulation by chronic lurasidone treatment. Psychopharmacology (Berl.), 2022, 239(8), 2547-2557.
[http://dx.doi.org/10.1007/s00213-022-06140-6] [PMID: 35459959]
[38]
Calabrese, V.; Cornelius, C.; Dinkova-Kostova, A.T.; Calabrese, E.J.; Mattson, M.P. Cellular stress responses, the hormesis paradigm, and vitagenes: Novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid. Redox Signal., 2010, 13(11), 1763-1811.
[http://dx.doi.org/10.1089/ars.2009.3074] [PMID: 20446769]
[39]
Drake, J.; Sultana, R.; Aksenova, M.; Calabrese, V.; Butterfield, D.A. Elevation of mitochondrial glutathione by? -glutamylcysteine ethyl ester protects mitochondria against peroxynitrite-induced oxidative stress. J. Neurosci. Res., 2003, 74(6), 917-927.
[http://dx.doi.org/10.1002/jnr.10810] [PMID: 14648597]
[40]
Raison, C.L.; Capuron, L.; Miller, A.H. Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol., 2006, 27(1), 24-31.
[http://dx.doi.org/10.1016/j.it.2005.11.006] [PMID: 16316783]
[41]
Slavich, G.M.; Irwin, M.R. From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. Psychol. Bull., 2014, 140(3), 774-815.
[http://dx.doi.org/10.1037/a0035302] [PMID: 24417575]
[42]
Furukawa, S.; Fujita, T.; Shimabukuro, M.; Iwaki, M.; Yamada, Y.; Nakajima, Y.; Nakayama, O.; Makishima, M.; Matsuda, M.; Shimomura, I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest., 2004, 114(12), 1752-1761.
[http://dx.doi.org/10.1172/JCI21625] [PMID: 15599400]
[43]
Everson, C.A.; Laatsch, C.D.; Hogg, N. Antioxidant defense responses to sleep loss and sleep recovery. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2005, 288(2), R374-R383.
[http://dx.doi.org/10.1152/ajpregu.00565.2004] [PMID: 15472007]
[44]
Hill, V.M.; O’Connor, R.M.; Sissoko, G.B.; Irobunda, I.S.; Leong, S.; Canman, J.C.; Stavropoulos, N.; Shirasu-Hiza, M. A bidirectional relationship between sleep and oxidative stress in Drosophila. PLoS Biol., 2018, 16(7), e2005206.
[http://dx.doi.org/10.1371/journal.pbio.2005206] [PMID: 30001323]
[45]
Cirelli, C. Sleep disruption, oxidative stress, and aging: New insights from fruit flies. Proc. Natl. Acad. Sci. USA, 2006, 103(38), 13901-13902.
[http://dx.doi.org/10.1073/pnas.0606652103] [PMID: 16966597]
[46]
Goldstein, B.I.; Kemp, D.E.; Soczynska, J.K.; McIntyre, R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: A systematic review of the literature. J. Clin. Psychiatry, 2009, 70(8), 1078-1090.
[http://dx.doi.org/10.4088/JCP.08r04505] [PMID: 19497250]
[47]
Miquel, S.; Champ, C.; Day, J.; Aarts, E.; Bahr, B.A.; Bakker, M.; Bánáti, D.; Calabrese, V.; Cederholm, T.; Cryan, J.; Dye, L.; Farrimond, J.A.; Korosi, A.; Layé, S.; Maudsley, S.; Milenkovic, D.; Mohajeri, M.H.; Sijben, J.; Solomon, A.; Spencer, J.P.E.; Thuret, S.; Vanden, B.W.; Vauzour, D.; Vellas, B.; Wesnes, K.; Willatts, P.; Wittenberg, R.; Geurts, L. Poor cognitive ageing: Vulnerabilities, mechanisms and the impact of nutritional interventions. Ageing Res. Rev., 2018, 42, 40-55.
[http://dx.doi.org/10.1016/j.arr.2017.12.004] [PMID: 29248758]
[48]
Soreca, I. Circadian rhythms and sleep in bipolar disorder. Curr. Opin. Psychiatry, 2014, 27(6), 467-471.
[http://dx.doi.org/10.1097/YCO.0000000000000108] [PMID: 25211500]
[49]
McIntyre, R.S.; Cucchiaro, J.; Pikalov, A.; Kroger, H.; Loebel, A. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J. Clin. Psychiatry, 2015, 76(4), 398-405.
[http://dx.doi.org/10.4088/JCP.14m09410] [PMID: 25844756]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy